

# Steven G Dubois

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1232989/publications.pdf>

Version: 2024-02-01

86  
papers

3,621  
citations

136950

32  
h-index

144013

57  
g-index

88  
all docs

88  
docs citations

88  
times ranked

5870  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to J.-G. Wang et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102922.	1.6	0
2	High-Risk Ewing Sarcoma: It Is Time to Break the Ceiling. <i>Journal of Clinical Oncology</i> , 2022, 40, 2288-2290.	1.6	4
3	High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 768-780.	3.8	19
4	Gamma Secretase Inhibition for a Child With Metastatic Glomus Tumor and Activated NOTCH1. <i>JCO Precision Oncology</i> , 2022, , .	3.0	3
5	The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1453-1459.	6.3	39
6	Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28834.	1.5	3
7	Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1396-1405.	0.8	12
8	Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 621-634.	2.3	3
9	Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1564-1568.	2.5	4
10	Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. <i>Cancer Medicine</i> , 2021, 10, 2310-2318.	2.8	7
11	Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1685.	2.4	101
12	Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 343-352.	1.6	2
13	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3514.	1.6	38
14	Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 2525-2527.	1.6	4
15	Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. <i>Journal of Clinical Oncology</i> , 2021, 39, 3822-3828.	1.6	4
16	NUT Carcinoma Without Upfront Surgical Resection: A Case Report. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e707-e710.	0.6	12
17	Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. <i>Journal of Clinical Oncology</i> , 2021, 39, 4029-4038.	1.6	41
18	Belzutifan, a Potent HIF2 $\alpha$ Inhibitor, in the Pacak—Zhuang Syndrome. <i>New England Journal of Medicine</i> , 2021, 385, 2059-2065.	27.0	36

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1â€“2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 121-133.	10.7	204
20	The use of intervalâ€“compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28559.	1.5	13
21	Trends in conditional survival and predictors of late death in neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28329.	1.5	6
22	Offâ€“label prescribing of targeted anticancer therapy at a large pediatric cancer center. <i>Cancer Medicine</i> , 2020, 9, 6658-6666.	2.8	15
23	The RACE to accelerate drug development for children with cancer. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 714-716.	5.6	7
24	Landscape of phase 1 clinical trials for minors with cancer in the United States. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28694.	1.5	7
25	Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. <i>Clinical Cancer Research</i> , 2020, 26, 2297-2307.	7.0	28
26	The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. <i>Paediatric Drugs</i> , 2020, 22, 189-197.	3.1	18
27	Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics. <i>AAPS Journal</i> , 2020, 22, 31.	4.4	11
28	An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz094.	2.9	114
29	DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. <i>Modern Pathology</i> , 2020, 33, 1910-1921.	5.5	40
30	Sponsorship of oncology clinical trials in the United States according to age of eligibility. <i>Cancer Medicine</i> , 2020, 9, 4495-4500.	2.8	9
31	How to address challenges and opportunities in pediatric cancer drug development?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 869-872.	5.0	1
32	Second malignancies in patients treated for Ewing sarcoma: A systematic review. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27938.	1.5	11
33	A Novel <i>ALK</i> Fusion in Pediatric Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2019, 29, 1704-1707.	4.5	19
34	Timing of first-in-child trials of FDA-approved oncology drugs. <i>European Journal of Cancer</i> , 2019, 112, 49-56.	2.8	49
35	Winning the RACE: Expanding pediatric cancer drug approvals. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27705.	1.5	6
36	Ushering in the next generation of precision trials for pediatric cancer. <i>Science</i> , 2019, 363, 1175-1181.	12.6	41

#	ARTICLE	IF	CITATIONS
37	Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). <i>European Journal of Cancer</i> , 2019, 112, 66-79.	2.8	49
38	Duality of Purpose: Participant and Parent Understanding of the Purpose of Genomic Tumor Profiling Research Among Children and Young Adults With Solid Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-17.	3.0	11
39	Risk stratification by somatic mutation burden in Ewing sarcoma. <i>Cancer</i> , 2019, 125, 1357-1364.	4.1	18
40	Clinical Impact of Tumor Mutational Burden in Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 695-699.	6.3	29
41	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27023.	1.5	31
42	Neuroblastoma and Histone Demethylation. <i>New England Journal of Medicine</i> , 2018, 379, 1476-1477.	27.0	2
43	The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. <i>Cancer</i> , 2018, 124, 4241-4247.	4.1	100
44	Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. <i>Sarcoma</i> , 2018, 2018, 1-6.	1.3	14
45	Dual HDAC and PI3K Inhibition Abrogates NF $\kappa$ B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. <i>Cancer Research</i> , 2018, 78, 4007-4021.	0.9	60
46	Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. <i>British Journal of Cancer</i> , 2018, 119, 615-621.	6.4	83
47	Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27251.	1.5	30
48	Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 270-277.	0.8	20
49	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	1.6	318
50	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26545.	1.5	30
51	Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Cancer</i> , 2017, 123, 4224-4235.	4.1	97
52	Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 231-237.	0.8	47
53	Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma. <i>Sarcoma</i> , 2017, 2017, 1-7.	1.3	4
54	Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. <i>Oncotarget</i> , 2017, 8, 23851-23861.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Clinical Characteristics and Outcomes of Pediatric Patients with Desmoplastic Small round Cell Tumor. <i>Rare Tumors</i> , 2016, 8, 24-26.	0.6	28
56	Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1771-1779.	1.5	81
57	Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. <i>Journal of Surgical Oncology</i> , 2016, 113, 351-354.	1.7	10
58	Conditional Survival and Predictors of Late Death in Patients With Ewing Sarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1091-1095.	1.5	15
59	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. <i>Cancer Genetics</i> , 2016, 209, 182-194.	0.4	38
60	Identification of Discrete Prognostic Groups in Ewing Sarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 47-53.	1.5	46
61	Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1974-1982.	1.5	49
62	Reply: Is Extended Sedation Necessary for Young Children Receiving High-dose <sup>131</sup> I-MIBG Therapy?. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1868-1868.	1.5	0
63	Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania. <i>Pediatric Blood and Cancer</i> , 2016, 63, 458-464.	1.5	1
64	Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving <sup>131</sup> I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 471-478.	1.5	7
65	Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors. <i>JAMA Oncology</i> , 2016, 2, 608.	7.1	172
66	Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. <i>Radiology</i> , 2016, 280, 905-915.	7.3	39
67	Increased risk of second malignant neoplasms in adolescents and young adults with cancer. <i>Cancer</i> , 2016, 122, 116-123.	4.1	118
68	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2016, 22, 3643-3650.	7.0	23
69	A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. <i>Clinical Cancer Research</i> , 2016, 22, 4014-4022.	7.0	56
70	Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to) Tumor Therapy (NANT-TT) Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1000-1007.	0.6	10
71	Intraoperative radiotherapy and limb-sparing surgery in the treatment of primary, non-metastatic extremity soft tissue sarcoma. <i>Journal of Radiation Oncology</i> , 2015, 4, 299-307.	0.7	0
72	Second malignant neoplasms among children, adolescents and young adults with Wilms tumor. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1259-1264.	1.5	25

#	ARTICLE	IF	CITATIONS
73	Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1947-1951.	1.5	14
74	Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. <i>Journal of Clinical Oncology</i> , 2014, 32, 3169-3176.	1.6	154
75	Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2012, 58, 181-184.	1.5	17
76	Evaluation of polymorphisms in <i>EWSR1</i> and risk of Ewing sarcoma: A report from the childhood cancer survivor study. <i>Pediatric Blood and Cancer</i> , 2012, 59, 52-56.	1.5	7
77	Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1021-1027.	2.3	31
78	Clinical features and outcomes in patients with extraskeletal ewing sarcoma. <i>Cancer</i> , 2011, 117, 3027-3032.	4.1	188
79	Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2011, 17, 5113-5122.	7.0	104
80	Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2009, 52, 324-327.	1.5	67
81	Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. <i>Pediatric Blood and Cancer</i> , 2008, 51, 589-592.	1.5	58
82	Late Recurrence of Ewing Sarcoma During Pregnancy. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 716-718.	0.6	11
83	Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium. <i>Blood</i> , 2008, 112, 1919-1919.	1.4	4
84	Markers of angiogenesis and clinical features in patients with sarcoma. <i>Cancer</i> , 2007, 109, 813-819.	4.1	131
85	Hematologic Toxicity of High-Dose Iodine-131-Metaiodobenzylguanidine Therapy for Advanced Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 2452-2460.	1.6	107
86	Pediatric Acute Blastic Natural Killer Cell Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 901-906.	1.3	21